Citations

Clear

6274 citation(s) found for "To, Andrew".

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Pemmaraju, Naveen , Kantarjian, Hagop M. , Sweet, Kendra , Senapati, Jayastu , Konopleva, Marina , Frankel, Arthur E. , Gupta, Vikas , Ulrickson, Matthew L. , Gorak, Edward J., Bhatia, Sumeet, Budak-Alpdoǧan, Tülin , Mason, James R. , García‐Romero, María Teresa , López‐Santiago, Norma, Vachhani, Pankit , Lee, Sangmin , Blum, William , Walter, Roland B. , Bixby, Dale L. , Gojo, Ivana , Rampal, Raajit K. , Foran, James M. , Fathi, Amir T. , Hall, Aric C. , Jacoby, Meagan A., Mannis, Gabriel N. , Stein, Anthony S. , Rizzieri, David A. , Olin, Rebecca L. , Perl, Alexander E. , Schiller, Gary J. , Shami, Paul J. , Stone, Richard M. , Wieduwilt, Matthew J. , Vasu, Sumithira , Khoury, Joseph D. , Qazilbash, Muzaffar H. , Cuglievan, Branko , Madanat, Yazan F. , Kharfan‐Dabaja, Mohamed A. , Tallman, Martin S. , Dhakal, Prajwal , Senapati, Jayastu , Konopleva, Marina , Gupta, Vikas , Budak-Alpdogan, Tulin , Garcia-Romero, Maria Teresa , Cesarman-Maus, Gabriela , Vachhani, Pankit , Bhatt, Vijaya Raj , Walter, Roland B , Fathi, Amir T , Hall, Aric Cameron , Mims, Alice S , Rizzieri, David A , Perl, Alexander E , Strickland, Stephen Anthony , Daver, Naval , Guzmán, Mónica L. , Roboz, Gail J , Khoury, Joseph , Aung, Phyu P , Madanat, Yazan , Kharfan-Dabaja, Mohamed A , Pawlowska, Anna , Taylor, Justin , Dhakal, Prajwal , Lane, Andrew A , Kantarjian, Hagop , Wang, Eunice S. , Wilson, Nathaniel R. , Mesa, Ruben A. , Cesarman‐Maus, Gabriela , Bhatt, Vijaya Raj , Duvic, Madeleine , Lima, Marcos de , Lancet, Jeffrey E. , Daver, Naval , Ravandi, Farhad , Roboz, Gail J. , Lane, Andrew A.

Mayo Clinic

Blood | November 18, 2022 | Volume: 141 | Issue: 6 | Pages: 567-578

10.1182/blood.2022017865 | PMID 36399715 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Impact of Recipient Age at Liver Transplant on Long-term Outcomes
Niazi, Shehzad K. , Brennan, Emily , Spaulding, Aaron , Borkar, Shalmali R. , Vasquez, Adriana , Schneekloth, Terry D. , Crook, Julia, Borkar, Shalmali, Keaveny, Andrew, Schneekloth, Terry, Taner, C. Burcin , Spaulding, Aaron , Crook, Julia E. , Keaveny, Andrew P. , Gentry, Melanie T

Mayo Clinic

Transplantation | November 18, 2022 | Volume: 107 | Issue: 3 | Pages: 654-663

10.1097/tp.0000000000004426 | PMID 36398331 Get It

Background. The age of a liver transplant (LT) candidate is one of many variables used in the transplant selection process. Most research about the age at transplant has used prespecified age ranges or categories in assessing associations with transplant outcomes. However, there is a lack of knowledge about the age at transplant and survival. This study aimed to examine associations of age at transplant as a continuous variable, in conjunction with other patient and disease-related factors, with patient and graft survival after LT. Methods. We used the Standard Transplant Analysis and Research data to identify LT recipients between January 2002 and June 2018. Cox regression models with a restricted cubic spline term for age examined associations with graft and patient survival after LT. We assessed the interactions of age with recipients’ sex, race/ethnicity, region, indication for transplant, body mass index, model for end-stage liver disease score, diabetes, functional status at transplant, and donor risk index. Results. Age at the time of LT showed a nonlinear association with both graft and patient survival. Each demographic, clinical, transplant-related, and donor-related factor influenced these relationships differently. Conclusions. Our results suggest that some older LT candidates may be better than some younger candidates and that clinicians should not exclusively use age to determine who receives LT.
Changes in Glomerular Volume, Sclerosis, and Ischemia at 5 Years after Kidney Transplantation: Incidence and Correlation with Late Graft Failure
Đenić, Aleksandar , Bogojevic, Marija , Subramani, Rashmi , Smith, Byron H. , Alexander, Mariam P., Grande, Joseph P. , Kukla, Aleksandra , Bentall, Andrew , Alexander, Mariam P. , Smith, Byron , Alexander, Mariam P , Grande, Joseph P , Kukla, Aleksandra , Bentall, Andrew , Rule, Andrew D , Denic, Aleksandar , Park, Walter D. , Schinstock, Carrie A. , Rule, Andrew D. , Stegall, Mark D.

Mayo Clinic

Journal of the American Society of Nephrology | November 17, 2022 | Volume: 34 | Issue: 2 | Pages: 346-358

10.1681/asn.2022040418 | PMID 36396330 Get It

Significance Statement Glomerular volume, ischemic glomeruli, and global glomerulosclerosis are not consistently assessed on kidney transplant biopsies. The authors evaluated morphometric measures of glomerular volume, the percentage of global glomerulosclerosis, and the percentage of ischemic glomeruli and assessed changes in these measures over time to determine whether such changes predict late allograft failure. All three features increased from transplant to five-year biopsy. Kidneys with smaller glomeruli at 5 years had more global glomerulosclerosis and a higher percentage of ischemic-appearing glomeruli. Smaller glomeruli and increasing percentages of global glomerulosclerosis and ischemic glomeruli at 5 years predicted allograft failure. Only increased percentage of ischemic glomeruli predicted allograft failure at 5 years independent of all Banff scores. Glomerular changes reflect pathologic processes that predicted allograft loss; measuring them quantitatively might enhance the current Banff system and provide biomarkers for intervention trials. Background Histology can provide insight into the biology of renal allograft loss. However, studies are lacking that use quantitative morphometry to simultaneously assess changes in mean glomerular volume and in the percentages of globally sclerosed glomeruli (GSG) and ischemic-appearing glomeruli in surveillance biopsies over time to determine whether such changes are correlated with late graft failure. Methods We used digital scans of surveillance biopsies (at implantation and at 1 and 5 years after transplantation) to morphometrically quantify glomerular volume and the percentages of GSG and ischemic-appearing glomeruli in a cohort of 835 kidney transplants. Cox proportional hazards models assessed the risk of allograft failure with these three glomerular features. Results From implantation to 5 years, mean glomerular volume increased by nearly 30% (from 2.8×10 6 to 3.6×10 6 µm 3 ), mean percentage of GSG increased from 3.2% to 13.2%, and mean percentage of ischemic-appearing glomeruli increased from 0.8% to 9.5%. Higher percentages of GSG and ischemic-appearing glomeruli at 5-year biopsy predicted allograft loss. The three glomerular features at 5-year biopsy were related; the percentage of GSG and the percentage of ischemic glomeruli were positively correlated, and both were inversely correlated to glomerular volume. At 5 years, only 5.3% of biopsies had ≥40% ischemic glomeruli, but 45% of these grafts failed (versus 11.6% for <40% ischemic glomeruli). Higher Banff scores were more common with increasing percentages of GSG and ischemia, but at 5 years, only the percentage of ischemic glomeruli added to predictive models adjusted for Banff scores. Conclusions Glomerular changes reflect important pathologic processes that predict graft loss. Measuring glomerular changes quantitatively on surveillance biopsies, especially the proportion of ischemic-appearing glomeruli, may enhance the current Banff system and be a useful surrogate end point for clinical intervention trials. Podcast This article contains a podcast at
Technical note: Phantom‐based training framework for convolutional neural network CT noise reduction
Huber, Nathan R. , Missert, Andrew D., Gong, Hao , Yu, Lifeng , Missert, Andrew D., Leng, Shuai , Yu, Lifeng , McCollough, Cynthia H.

Mayo Clinic

Medical Physics | November 17, 2022 | Volume: 50 | Issue: 2 | Pages: 821-830

10.1002/mp.16093 | PMID 36385704 Get It

AbstractBackgroundDeep artificial neural networks such as convolutional neural networks (CNNs) have been shown to be effective models for reducing noise in CT images while preserving anatomic details. A practical bottleneck for developing CNN‐based denoising models is the procurement of training data consisting of paired examples of high‐noise and low‐noise CT images. Obtaining these paired data are not practical in a clinical setting where the raw projection data is not available. This work outlines a technique to optimize CNN denoising models using methods that are available in a routine clinical setting.PurposeTo demonstrate a phantom‐based training framework for CNN noise reduction that can be efficiently implemented on any CT scanner.MethodsThe phantom‐based training framework uses supervised learning in which training data are synthesized using an image‐based noise insertion technique. Ten patient image series were used for training and validation (9:1) and noise‐only images obtained from anthropomorphic phantom scans. Phantom noise‐only images were superimposed on patient images to imitate low‐dose CT images for use in training. A modified U‐Net architecture was used with mean‐squared‐error and feature reconstruction loss. The training framework was tested for clinically indicated whole‐body‐low‐dose CT images, as well as routine abdomen‐pelvis exams for which projection data was unavailable. Performance was assessed based on root‐mean‐square error, structural similarity, line profiles, and visual assessment.ResultsWhen the CNN was tested on five reserved quarter‐dose whole‐body‐low‐dose CT images, noise was reduced by 75%, root‐mean‐square‐error reduced by 34%, and structural similarity increased by 60%. Visual analysis and line profiles indicated that the method significantly reduced noise while maintaining spatial resolution of anatomic features.ConclusionThe proposed phantom‐based training framework demonstrated strong noise reduction while preserving spatial detail. Because this method is based within the image domain, it can be easily implemented without access to projection data.
Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer
Rodriguez, Nicolette J. , Furniss, C. Sloane , Yurgelun, Matthew B. , Constantinou, Pamela E., Fortes, Ileana, Caruso, Alyson , Stopfer, Jill E. , Underhill‐Blazey, Meghan , Kenner, Barbara , Nelson, Scott H., Okumura, Sydney, Coffin, Tara B. , Ocean, Allyson J. , McAllister, Florencia , Lowy, Andrew M. , Lippman, Scott M. , Madlensky, Lisa , Petersen, Gloria M. , Ukaegbu, Chinedu I. , Schwartz, Alison , Nelson, Scott H., Zhou, Alicia Yiran , Uno, Hajime , Horiguchi, Miki , Klein, Alison P. , Garber, Judy E. , Goggins, Michael , Maitra, Anirban , Syngal, Sapna

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: A029-A029

10.1158/1538-7445.panca22-a029 Get It

Abstract Background: Uptake of genetic testing for cancer susceptibility in family members of cancer patients is suboptimal. The GENetic Education, Risk Assessment, and TEsting (GENERATE) study evaluated two strategies of remote genetic education and testing in relatives of pancreatic ductal adenocarcinoma (PDAC) patients. Methods: Eligible participants had: a first-degree relative with PDAC or had a known pathogenic germline variant (PGV) in one of thirteen PDAC predisposition genes (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53) and a first- or second-degree relative with PDAC. Participants were cluster-randomized by family into one of two arms. Arm 1 included an interactive telemedicine session with a genetic counselor, followed by genetic testing at a commercial laboratory. Arm 2 involved remote online genetic education and testing at the commercial laboratory without the interactive session. The primary outcome was uptake of genetic testing across study arms, which was compared by permutation tests and mixed-effects logistic regression models. Results: Between 5/8/2019 and 6/1/2021, 424 families were randomized, including 601 participants (n=296 Arm 1; n=305 Arm 2). The uptake of genetic testing was 87% (257/296) in Arm 1 and 93% (284/305) in Arm 2 (p=0.014). Participants in Arm 1 were significantly less likely to obtain genetic testing compared to Arm 2 (Adjusted ratio [Arm1/Arm2] 0.90, 95% confidence interval 0.78-0.98). BRCA2, ATM, CDKN2A and PALB2 were the most common PDAC susceptibility genes in which PGVs were identified. Conclusions: Remote methods of genetic education and testing are successful alternatives to traditional germline susceptibility testing. Citation Format: Nicolette J. Rodriguez, C. Sloane Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Ileana Fortes, Alyson Caruso, Alison N. Schwartz, Jill E. Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott H. Nelson, Sydney Okumura, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Miki Horiguchi, Allyson J. Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal. A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A029.
SURG-12. SURGICAL INTERVENTION FOR PRIMARY B-CELL LYMPHOMA OF THE SPINE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL PRESENTATION, HISTOLOGICAL MARKERS, TREATMENTS, AND SURVIVAL OUTCOMES
Patel, Neal , Sahyouni, Ronald , Gendreau, Julian , Brown, Nolan J. , Lee, Seung Jin , Chan, Andrew

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii253-vii254

10.1093/neuonc/noac209.978 Get It

Abstract B-cell lymphoma is a potential cause of spinal cord compression that presents with nonspecific symptoms and inconsistent imaging findings. Surgical decompression is a mainstay for both diagnosis and management especially in patients with acute neurologic deficits; however, the long-term efficacy of intervention is still unclear. We perform a systematic review of the clinical symptoms, radiographic findings, and outcome after spinal decompression in B-cell lymphoma. The databases of Medline, PubMed, and the Cochrane Database of Systemic Reviews were queried for all articles reporting spinal B-cell lymphoma. Data on presenting symptoms, histological markers, treatment and survival outcomes were extracted. Bivariate and Multivariate Cox survival regression models and Kaplan-Meier curves were generated using R software survival package. In total, 57 studies were included with 72 patients diagnosed with spinal B-cell lymphoma. Mean age was 56.22 (IQR: 45.00-70.25) with 68% of patients being male and 4.2% of patients being immunocompromised. Back pain was the most common symptom (74%) with B symptoms and cauda equina symptoms present in only 6% and 29% respectively. Mean length of symptoms before presentation was 3.81 months (IQR: 0.45-3.25). The most common location was the thoracic spine (53%), with a majority of the lesions being hyperintense (28%) on T2 MRI. Surgical resection was performed in 83% of patients. Symptoms improved in 88% of patients after surgery and 80% of patients treated nonoperatively. OS at one- and five-years was 85% (95% CI: 0.749-0.953; n=72) and 66% (95% CI: 0.512-0.847; n=72), respectively. Age &gt; 70 was associated with poorer OS in bivariate (HR 4.07 [95% CI: 1.328-12.46], p &lt; 0.01; n=72) and multivariate analysis (HR 3.829 [95% CI: 1.158-12.662], p &lt; 0.03; n=72). Primary spinal B-cell lymphoma can have a variety of presentations. Both surgery and nonoperative management may have similar improvement in symptoms. Age &gt; 70 appears to confer poorer OS.
SURG-31. UTILITY OF TRANEXAMIC ACID (TXA) FOR RESECTION OF INTRACRANIAL MENINGIOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Nguyen, Brandon , Harris, Mark, Mohyeldin, Ahmed, Brown, Nolan J. , Nguyen, Andrew, Beyer, Ryan S. , Singh, Rohin , Shahrestani, Shane

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii258-vii258

10.1093/neuonc/noac209.996 Get It

Abstract Due to its anti-fibrinolytic action, tranexamic acid (TXA) can be utilized to help maintain hemostasis during surgical operations. With respect to surgery for intracranial tumors, we hypothesize that TXA could help mitigate blood loss during resection of highly vascular tumors such as meningiomas. We therefore conducted a systematic review of the literature and meta-analysis to analyze the effects of TXA administration in patients undergoing surgical resection of intracranial meningioma. Study inclusion criteria were (1) primary data articles describing use of TXA in surgical resection of meningioma. In this meta-analysis, which included four primary comparative studies, outcome measurements between TXA and non-TXA groups were compared. Primary outcomes included operative length, complications, transfusion requirements, estimated blood loss, and postoperative Hb for TXA versus non-TXA (control) groups. Pooled-comparative analysis was conducted for each of these perioperative variables and formal meta-analysis was applied toward statistically significant parameters. A total of 221 patients were analyzed (110 TXA, 111 non-TXA). Patient age (p = 0.1632), gender (p = 0.8317), and tumor location (p = -.8334) were similar for TXA and control groups. TXA was associated with decreased complication rate (logRR: -0.85; CI95% = -1.49 to -0.22; p = 0.0087), decreased transfusion requirement (logRR: -0.50; CI95% = -0.92 to -0.08; p = 0.0039), reduced blood loss (SMD: -1.76; CI95% = -3.21 to -0.31; p &lt; 0.0001), and increased postoperative Hb (SMD: 0.46; CI95% = -0.15 to 1.07; p &lt; 0.0001). In three trials, TXA was administered intravenously as a loading dose of 20 mg/kg for 20 minutes preoperatively with an intraoperative maintenance rate of 1mg/kg/hr; in one trial, administration design was identical except that infusion rate of the 20 mg/kg preoperative loading dose was unspecified. TXA may be associated with reduced complications, transfusion requirements, perioperative estimated blood loss, and increasedpostoperative Hb when administered perioperatively for surgical resection of intracranial meningiomas.
SURG-33. RATES OF PRE-OPERATIVE SEIZURE IN PATIENTS WITH MENINGIOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Nguyen, Brandon , Harris, Mark, Mohyeldin, Ahmed, Nguyen, Andrew, Brown, Nolan J. , Singh, Rohin , Shahrestani, Shane , Gendreau, Julian

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii259-vii259

10.1093/neuonc/noac209.998 Get It

Abstract Recent literature has primarily focused on the factors influencing postoperative seizures following resection of meningioma, but many patients also suffer seizures preoperatively. This meta-analysis examined patient demographics, tumor characteristics, and preoperative symptoms to determine which factors are most associated with preoperative seizures. A literature search of Pubmed, Web of Science, and Scopus was conducted. All randomized controlled trials, case-control studies, and cohort studies reporting on preoperative seizure in patients with meningioma were included for analysis. The initial search yielded 4129 total studies, 33 of which were included for quantitative analysis. A total of 8221 patients were analyzed and the rate of preoperative seizure was 26%. Patients were classified as adult vs pediatric and male vs female for analysis. Meningiomas were classified as midline/bilateral vs left-sided vs right-sided, WHO grade 1 vs grade 2-3, greater than 4 cm3 vs less than 4 cm3, and skull base vs non-skull base location. The preoperative signs and symptoms analyzed included presence of headaches, tumor-related edematous change, and neurological deficits. Preoperative seizures were more common in pediatric patients (p&lt; .02) and males (p&lt; .0001). Patients with tumors classified as midline (p&lt; .0001), WHO grade 2-3 (p&lt; .0001), larger than 4 cm3 (p&lt; .0001), and skull base location (p&lt; .0001) were more likely to experience preoperative seizures. Preoperative headaches (p&lt; .0001) were less common in patients with preoperative seizures. Edematous change (p&lt; .0001) and neurological deficits (P&lt; .0001) were more common in patients with pre-operative seizures. On assessment of risk for study bias, no publication bias was detected. This meta-analysis displayed that over 20% of meningioma patients suffer from preoperative seizures. Notably, pediatric patients, patients with midline and skull base meningiomas, and males of all ages were more likely to experience preoperative seizure. Interestingly, patients with preoperative seizures were less likely to experience headaches.
SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , O’Brien, Barbara , Sloan, Andrew, Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Groot, John de , Kim, Albert Sungsoo , Fecci, Peter E. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii256-vii257

10.1093/neuonc/noac209.989 Get It

Abstract Treatment options for glioblastoma remain limited, particularly for those who are not eligible for traditional resection, whether due to lesion location or inability to tolerate open craniotomy. Maximal-safe resection followed by radiation with concurrent and adjuvant temozolomide offers the best outcomes for patients. Unfortunately, not all tumors are amenable to conventional surgical resection at the time of diagnosis with only about 1/3 of patients able to receive a gross-total resection and 15-25% of patients receiving biopsy only, thus reducing their projected overall survival to 9 months. Laser interstitial thermal therapy (LITT) is a minimally invasive, cytoreductive tool, that has demonstrated safety as a surgical approach to treat primary brain tumors. METHODS Data from LAANTERN prospective multicenter registry (NCT02392078) was analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma (N=89). Demographics, intraprocedural data, adverse events, KPS, health-economics, and survival data were prospectively collected then analyzed separately for newly diagnosed GBM (N=29) and recurrent GBM (N=60). RESULTS Median overall-survival was 9.73 months (95% CI: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 (6.94, 12.36) months for recurrent patients. Median overall-survival for newly diagnosed patients receiving post-LITT chemoradiotherapy was 16.14 months (6.11, not reached). The median length of hospital stay was 50 hours and 80% of patients were discharged to home. CONCLUSIONS LITT offers an effective cytoreductive approach for patients with newly diagnosed and recurrent IDH wild-type glioblastoma. Importantly, its use in newly diagnosed patients who receive post-LITT chemoradiotherapy leads to a median OS similar to that of patients treated with conventional surgical resection. LITT remains an important alternative for patients with inoperable tumors or those not amenable to resection. Enrollment in LAANTERN is ongoing and these cohorts will be revisited as data continues to mature. Benefits beyond cytoreduction are also being actively explored.
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Ashkan, Keyoumars, Campian, Jian , Trusheim, John, Tran, David , Anstass, George, Cobbs, Charles , Heth, Jason , Salacz, Michael, D’Andre, Stacy D. , Aiken, Robert, Moshel, Yaron A., Nam, Jooyeon, Pillainayagam, Clement, Wagner, Stephanie A., Walter, Kevin A. , Chaudary, Rekha, Goldlust, Samuel , Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin O. , Mikkelsen, Tom , Walbert, Tobias , Abram, Steve, Ewend, Matthew G., Khagi, Simon , Lovick, Darren, Kim, Lyndon, Loudon, William G. , Martinez, Nina , Thompson, Reid, Avigan, David , Fink, Karen, Geoffroy, Francois J., Giglio, Pierre , Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott , Nadji‐Ohl, Minou , Sanchin, Lhagva, Sloan, Andrew, Bosch, Marnix L. , Liau, Linda M. , Brem, Steven , IWAMOTO, FABIO MASSAITI , Tran, David D. , Lee, Ian , Bota, Daniela A. , Brenner, Andrew Jacob , Portnow, Jana , Lutzky, Jose , Meisel, Hans Jörg

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii66-vii66

10.1093/neuonc/noac209.259 Get It

Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years. We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and METHODS Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo. Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo. The primary and secondary endpoints compare overall survival (OS) with contemporaneous, matched external controls. Four sets of analyses were conducted to ensure rigorous matching of the controls, reduce biases, and confirm the robustness of the results. RESULTS 331 patients were enrolled. With the crossover, 89% received murcidencel. Median OS (mOS) for nGBM patients (n = 232) was 19.3 months from randomization (22.4 months from surgery) with murcidencel vs. 16.5 months from randomization in the controls (HR = 0.80, p = 0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For rGBM (n = 64), mOS was 13.2 months from relapse vs. 7.8 months in the controls (HR = 0.58, p &lt; 0.001). Survival at 24 months post-recurrence was 20.7% vs. 9.6%, and at 30 months post-recurrence was 11.1% vs 5.1%. In nGBM patients with methylated MGMT (n = 90), mOS was 30.2 months from randomization (33 months from surgery) with murcidencel vs. 21.3 months from randomization in the controls (HR = 0.74, p = 0.027). The treatment was well tolerated, with only 5 serious adverse events deemed at least possibly related to the vaccine. CONCLUSION Clinically meaningful and statistically significant survival extension was seen in both nGBM and rGBM patients treated with murcidencel and SOC compared with contemporaneous, matched external controls who received SOC alone.